Phase I/II Study of S-1 plus Cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer

Japanese Journal of Clinical Oncology

Volumn 40, Issue 3, 2009, Pages 214-221

  Fujii, Masato ^a   Tomita, Kitinobu ^b   Nishijima, Wataru ^c   Tsukuda, Mamoru ^d   Hasegawa, Yasuhisa ^e   Ishitoya, Junichi ^f   Yamane, Hideo ^g   Homma, Akihiro ^h   Tomita, Toshiki ⁱ  

^a NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c SAITAMA CANCER CENTER   (Japan)

^d YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^g OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CDDP; Chemotherapy; Head and neck cancer; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; ANTINEOPLASTIC AGENT; OXONIC ACID; S 1 (COMBINATION); TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BEDTIME DOSAGE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPERPIGMENTATION; LEUKOPENIA; MALE; MORNING DOSAGE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RASH; RECOMMENDED DRUG DOSE; RECURRENT CANCER; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; BONE TUMOR; CANCER STAGING; DRUG COMBINATION; FOLLOW UP; HEAD AND NECK TUMOR; INTRAVENOUS DRUG ADMINISTRATION; LIVER TUMOR; LUNG TUMOR; MAXIMUM TOLERATED DOSE; METASTASIS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OXONIC ACID; PROGNOSIS; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950360911     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp153     Document Type: Article

References (34)

1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-94.
2. Wittes RE, Cvitkovic E, Shah J, Gerold FP, Strong EW. cis-Dichlorodiammineplatinum (II) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treat Rep 1977;61:359-66.
3. Jacobs C, Lyman G, Velez-García E, Sridhar KS, Knight W, Hochster H, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257-63.
4. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245-51.
5. Kish J, Drelichman A, Jacobs J, Hoschner J, Kinzie J, Loh J, et al. Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep 1982;66:471-4.
6. Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 1993;85:95-111.
7. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994;86:265-72.
8. Wang HM, Wang CH, Chen JS, Chang HK, Kiu MC, Liaw CC, et al. Cisplatin and 5-fluorouracil as neoadjuvant chemotherapy: predicting response in head and neck squamous cell cancer. J Formos Med Assoc 1995;94:87-94.
9. Schrijvers D, Johnson J, Jiminez U, Gore M, Kosmidis P, Szpirglas H, et al. Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 1998;16:1054-9.
10. Shirasaka T, Shimamoto Y, Ohshimo H, Saito H, Fukushima M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993;32:167-72.
11. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B. Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group). Gan to kagaku ryoho 1998;25:1151-8.
12. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B. Late phase II study of S-1 in patients with advanced head and neck cancer. Gan to kagaku ryoho 2001;28:1381-90.
13. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T, et al. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20.
14. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000;58:191-7.
15. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, et al. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 2000;83:141-5.
16. Shirao K, Ohtsu A, Takada H, Mitachi Y, Hirakawa K, Horikoshi N, et al. Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 2004;100:2355-61.
17. Furuse K, Kawahara M, Hasegawa K, Kudoh S, Takada M, Sugiura T, et al. Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer. Int J Clin Oncol 2001;6:236-41.
18. Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 2001;85:939-43.
19. Saek T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S, et al. A phase II study of S-1 in patients with metastatic breast cancer, a Japanese trial by the S-1 Cooperative Study Group (Breast Cancer Working Group). Breast Cancer 2004;11:194-202.
20. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 2005;68:171-8.
21. Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S, et al. A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 2008;61:615-21.
22. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 2004;15:1769-74.
23. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89:2207-12.
24. Ichinose Y, Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M, et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 2004;10:7860-4.
25. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncology 2008;9:215-21.
26. Watanabe A, Taniguchi M, Yamashita T, Ueda M, Abe T, Kusumi T, et al. Phase I/II study of S-1 combined with carboplatin in recurrent and/or metastatic head and neck cancer as outpatient chemotherapy. Head Neck 2006;28:620-5.
27. Kodaira T, Fuwa N, Tachibana H, Hidano S. Phase I study of S-1 and nedaplatin for patients with recurrence of head and neck cancer. Anticancer Res 2006;26:2265-8.
28. Choi YJ, Chung JS, Shin HJ, Cho GJ, Wang SG, Lee BJ, et al. Induction chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. J Laryngol Oncol 2008;122:848-53.
29. Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere AA. Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 2002;20:1593-9.
30. Adamo V, Ferraro G, Pergolizzi S, Sergi C, Laudani A, Settineri N, et al. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncology 2004;40:525-31.
31. Tahara M, Minami H, Kawada K, Mukai H, Kawashima M, Ogino T, et al. Phase I trial of concurrent chemotherapy with S-1 and CDDP in patients with unresectable locally advanced squamous cell carcinoma of head and neck (SCCHN). American Society of Clinical Oncology (ASCO) Annual Meeting, 2005, 518s.
32. Tahara M. Concurrent chemotherapy (CRT) with S-1 and CDDP in patients with locally advanced head and neck cancer. Gan to kagaku ryoho 2006;33(Suppl. I):167-71.
33. Barbara B, Meredith AG, William F, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-54.
34. Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27:1864-71.